Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Investor Presentation (June 2026)
19 slides from Gujarat Themis Biosyn's investor presentation, Jun 29, 2026
Slide 1: Regulation 30 cover letter: Investor Presentation
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2026-27/33 29th June, 2026 Corporate Relationship Department Listing Department BS
Slide 2: Gujarat Themis Biosyn Limited Roadshow Presentation
Gujarat Themis Biosyn Limited Roadshow Presentation June 2026
Slide 3: Glossary
Click to edit Master title style Glossary Abbreviations Abbreviations ADC Antibody Drug Conjugation FY Financial Year (1st April – 31st March) API Active Pharmaceutical Ingredient GIIC Ltd. Gujarat Industrial Investment Corporation Limited CDMO Contract Development and Manufacturing Organization GMP
Slide 4: Track to become a Diversified Pharma Platform
Click to edit GTBL onMaster title style Track to become a Diversified Pharma Platform Enhancing Fermentation Capabilities Forward Integration Gujarat Themis Biosyn Limited Acquisition of Sanofi’s Select Acquisition of MicroBiopharm Japan(1) Product Portfolio(1) Product Portfolio Expansion of Technic
Slide 5: Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited
Slide 6: Intermediates - Snapshot, Product Portfolio and Key Highlights
Click to edit GTBL Master title style - Snapshot 1 Product Portfolio Key Highlights Intermediate for Anti-Tuberculosis Rifamycin S Intermediates Used for manufacturing drug Rifampicin (Antibiotic used for treatment of bacterial infections, including tuberculosis) 1 990 KL 235 Manufacturing Site Annu
Slide 7: Growth Drivers
Click to edit Master Growth Drivers title style R&D Driven Innovation & Forward Integration New Infrastructure Development Strategic ESG & Cost optimization initiative Geographical Diversification Enhance Capacity to meet future growth 6
Slide 8: Financials
Click to edit Master title style Financials Revenue from Operations (INR Lakhs) EBITDA(1) (INR Lakhs) and EBITDA Margin 16,982.19 46.36% 45.65% 45.55% 16,582.28 15,079.99 7,873.37 7,553.02 6,884.44 FY24 FY25 FY26 FY24 FY25 FY26 PAT (INR Lakhs) and PAT Margins Return on Capital Employed(2) and Return
Slide 9: Acquisition of MicroBiopharm Japan
Announced acquisition of Acquisition of MicroBiopharm Japan Note: Acquisition is subject to regulatory approvals
Slide 10: MicroBiopharm Japan Co. Ltd. - At a Glance and Strategic Rationale
Click to edit MasterJapan MicroBiopharm title Co. style Ltd. – At a Glance and Strategic Rationale Key Highlights Fermentation Key Strengths Microbial fermentation, large scale fermentation Customer Relationships 60+ 3 Plants JPY 9.5 Bn Average business relationship of over 25 years with top 5 custo
Slide 11: Synergies & Value Creation
Click to edit Master Synergies & Valuetitle style Creation 1 Enhanced Fermentation & Precision Biotech Capabilities 2 Expanded Product Portfolio & Therapeutic Coverage 3 CDMO Platform 4 Entry into Advanced Biologics & Novel Modalities 5 Access to Established Relationships with Pharmaceutical Compani
Slide 12: Acquisition of Sanofi's Select Product Portfolio
Announced acquisition of Anti-Tuberculosis and Anti-Infectives Portfolio Acquisition of Sanofi’s Select Product Portfolio Note: Acquisition is subject to regulatory approvals
Slide 13: Acquisition of Anti-Tuberculosis & Anti-Infectives Portfolio of Sanofi
Click to edit Master Acquisition title style & Anti-Infectives Portfolio of Sanofi of Anti-Tuberculosis About Key Operating Highlights ▪ GTBL has entered into an agreement with Sanofi (the French-holding company of the Sanofi group) to acquire select product portfolio ▪ Comprehensive Portfolio of Ma
Slide 14: Strategic Rationale
Click to edit Master Strategic title style Rationale A global footprint with a particular focus on Europe and Middle East & Africa 1 Immediate geographical expansion unlocked with reach to 59 countries, strong presence in Europe & MEA with entry into regulated markets Forward integration 2 Complemen
Slide 15: Annexures
Annexures
Slide 16: Profit and Loss Statement
Click to edit GTBL Master – Profit andtitle style Loss Statement INR Lakhs Particulars FY24 FY25 FY26 Income Revenue from operations (net) 16,982.19 15,079.99 16,582.28 Other income 436.57 243.24 242.81 Total Income 17,418.76 15,323.23 16,825.09 Expenses Cost of materials consumed 2,566.71 2,577.72
Slide 17: Balance Sheet
Click to edit GTBL MasterSheet – Balance title style INR Lakhs Particulars FY24 FY25 FY26 ASSETS Non-current Assets a. Property, Plant and Equipment 3,527.51 4,058.01 28,692.26 b. Capital Work-in-Progress 9,122.35 18,440.81 12,113.04 c. Right-of-use Assets 274.13 54.94 196.24 d. Other Intangible Ass
Slide 18: Cash Flow Statement
Click to edit GTBL Master – Cash Flowtitle style Statement INR Lakhs Particulars FY24 FY25 FY26 Cash Flow from Operating Activities: Profit before tax 7,933.43 6,553.79 6,209.00 Adjustments for: Depreciation and amortisation expense 406.35 565.24 1,291.93 Interest income classified as investing acti
Slide 19: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by the Gujarat Themis Biosyn Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe to the securities of the Company. No offering of securities
Gujarat Themis Biosyn — Investor Presentation (June 2026) on 6ix